Latest research
Latest corporate research
Latest tax advantaged reviews
Subscribe to our latest research
What we do
Investment research services
Tax enhanced research services
Bespoke consulting services
About
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact us
Our team
News & events
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact us
×
Latest corporate investment research
Detailed company analysis created specifically for investors
Latest tax advantaged research
Product reports for investors and advisors
Latest published research
Shield Therapeutics Plc
November 2024 Investor Forum
21st Nov 2024
Custodian Property Income REIT plc
November 2024 Investor Forum
20th Nov 2024
Services for corporates
Investment research & analysis
Detailed company analysis created specifically for investors
Bespoke valuation services
Bespoke valuation services
Services for clients with specific needs
Services for funds
Tax advantaged research
Product reports for investors and advisors.
About
About Hardman & Co.
We are the longest-established commissioned research provider.
Insights
Group
Created with Sketch.
Podcasts
Group
Created with Sketch.
Videos
Group
Created with Sketch.
Events
Group
Created with Sketch.
See all news
Group
Created with Sketch.
Podcast
The EIS Navigator
Latest Episode
105: Finding the venture opportunity in the energy transition | Reuben Wilcock of Blackfinch Ventures
Stay up-to-date with the latest research
Sign up to our newsletter
Life Sciences research
o2h Ventures
Life Sciences
The o2h Human Health EIS Knowledge Intensive Fund
29 Jun 2023
Shield Therapeutics Plc
Life Sciences
Reassuring 1Q’23 Accrufer prescriptions
By
Dr Martin Hall
17 May 2023
Stay up-to-date with the latest research
Sign up to our newsletter
Tissue Regenix
Life Sciences
Turning profitable and cash-generative
By
Dr Martin Hall
05 Apr 2023
Advanced Oncotherapy
Life Sciences
Understanding the significance of 230MeV
By
Dr Martin Hall
17 Jan 2023
Shield Therapeutics Plc
Life Sciences
Positioned for growth and profitability
By
Dr Martin Hall
13 Jan 2023
Life Sciences
Hardman & Co Healthcare Index
By
Dr Martin Hall
06 Jan 2023
International Biotechnology Trust
Life Sciences
Low FDA activity may drive further M&A
By
Dr Martin Hall
08 Dec 2022
Advanced Oncotherapy
Life Sciences
Major milestone achieved
By
Dr Martin Hall
29 Sep 2022
Tissue Regenix
Life Sciences
Operating leverage
By
Dr Martin Hall
27 Sep 2022
Shield Therapeutics Plc
Life Sciences
Accrufer momentum building
By
Dr Martin Hall
15 Sep 2022
Shield Therapeutics Plc
Life Sciences
Looking to accelerate positive signals in the US
By
Dr Martin Hall
26 Jul 2022
Prev
1
2
3
4
...
22
Next
